Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors

Brain Research

Volumn 726, Issue 1-2, 1996, Pages 207-212

  Svensson, Anne Lie ^a   Zhang, Xiao ^a   Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

AF DX 116; Atropine; Cortical synaptosome; In vitro ACh release; Muscarinic receptor; Pirenzepine; Tacrine

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ATROPINE; CHOLINESTERASE INHIBITOR; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; OTENZEPAD; PIRENZEPINE; POTASSIUM ION; TACRINE;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030575326     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00339-3     Document Type: Article

References (32)

1. [1] Adem, A., Mohammed, A.H., Winblad, B. and Henriksson, B.E., A novel anticholinesterase THB013: biochemical and behavioural studies, J. Neural. Transm. [P-D Sect]. 8 (1994) 139-148.
2. [2] Beani, L., Bianchi, C., Ferraro, L., Morari, M., Simonato, M., Spalloto, G. and Tanganelli, S., Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance, J. Pharmacol. Exp. Ther., 258 (1991) 472-476.
3. [3] Beani, L., Bianchi, C., Siniscalchi, A., Sivilotti, L., Tanganelli, S. and Veratti, E., Different approaches to study acetylcholine release: endogenous ACh versus tritium efflux, Naunyn Schmiedebergs Arch. Pharmacol., 328 (1984) 119-126.
4. [4] Buyukuysal, R.L. and Wurtman, R.J., Tetrahydroaminoacridine but not 4-aminopyridine inhibits high-affinity choline uptake in striatal and hippocampal synatosomes, Brain Res., 482 (1989) 371-375.
5. [5] Cowburn, R.F., O'Neill, C., Ravid, R., Alafuzoff, I., Winblad, B. and Fowler, C.J., Adenylyl cyclase activity in postmortem human brain: evidence of altered G-protein mediation in Alzheimer's disease. J. Neurochem., 58 (1992) 1409-1419.
6. + concentrations. Naunyn Schmiedebergs Arch. Pharmacol., 348 (1993) 228-233.
7. + current, Eur. J. Pharmacol., 141 (1987) 153-157.
8. [8] Ellman, G.L., Courtney, K.D., Anders, V. and Featherstone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity, Biochem. Pharmacol., 7 (1961) 88-95.
9. [9] Farlow, M., Gracon, S.I., Hershey, L.A., Lewis, K.W., Sadowsky, C.H. and DolanVreno, J., A controlled trial of tacrine in Alzheimer's disease, J. Am. Med. Assoc., 268 (1992) 2523-2529.
10. [10] Flynn, D.D. and Mash, D.C., Multiple in vitro interactions with and differential in vivo regulation of muscarinic receptor subtypes by tetrahydroaminoacridine, J. Pharmacol. Exp. Ther., 250 (1989) 573-581.
11. 3H]acetylcholine release from slices of rat hippocampus, striatum and cortex, Brain Res., 123 (1977) 311-322.
12. [12] Håkansson, L., Mechanism of action of cholinesterase inhibitors in Alzheimer's disease, Acta Neurol. Scand., suppl., 149 (1993) 7-9.
13. [13] Johansson, M., Hellström-Lindahl, E. and Nordberg, A., Steady-state pharmacokinetics of tacrine in long-term treatment of Alzheimer patients, Dementia, 7 (1996) 111-117.
14. [14] Johansson, M. and Nordberg, A., Pharmacokinetic studies of cholinesterase inhibitors, Acta Neurol. Scand., suppl., 149 (1993) 22-25.
15. [15] Jope, R.S., Song, L., Li, X., Impaired phosphoinositide hydrolysis in Alzheimer's disease brain, Neurobiol. Aging, 15 (1994) 221-226.
16. [16] Knapp, M.J., Knopman, D.S., Solomon, P.R., Pendlebury, W.W., Davis, C.S., Gracon, S.I., A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group, J. Am. Med. Assoc., 271 (1994) 985-991.
17. [17] Loiacono, R.E, and Mitchelson, F.J., Effect of nicotine and tacrine on acetylcholine release from rat cerebral cortical slices, Naunyn Schmiedebergs Arch. Pharmacol., 342 (1990) 31-35.
18. [18] Lowry, O.H., Rosenbrough, N.J., Farr, A.L. and Randall, R.J., Protein measurement with the Folin phenol reagent, J. Biol. Chem., 193 (1951) 265-275.
19. 3H]acetylcholine release from rat cortical synaptosomes, J. Neurosci., 5 (1985) 1202-1207.
20. 3H-acetylcholine from rat cerebral cortex slices in vitro. Br. J. Pharmacol., 47 (1973) 97-108.
21. [21] Mulder, A.H., Yamamura, H.I., Kuhar, M.J. and Snyder, S.H., Release of acetylcholine from hippocampal slices by potassium depolarization: dependence on high affinity choline uptake, Brain Res., 70 (1974) 372-376.
22. [22] Nielsen, J.A., Mena, E.E., Williams, I.H., Nocerini, M.R. and Liston, D., Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes, Eur. J. Pharmacol., 173 (1989) 53-64.
23. [23] Nilsson, L., Adem, A., Hardy, J., Winblad, B. and Nordberg, A., Do tertahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brain via nicotinic receptors?, J. Neural. Transm., 70 (1987) 357-368.
24. [24] Nordberg A., THA - A potential drug in the treatment of Alzheimer's disease. In J. Massoulie, F. Barou, E. Barnard, A. Chatonnet, B. Doctor and D.M. Quinn (Eds.). Cholinesterases: Structure, Function, Mechanism, Genetics and Cell Biology, American Chemical Society, Washington, DC, 1991, pp. 327-331.
25. [25] Pearce, B.D. and Potter, L.T., Coupling of m1 muscarinic receptors to G-protein in Alzheimer's disease, Alzheimer Dis. Assoc. Disord., 5 (1991) 163-172.
26. [26] Perry, E.K., Smith, C.J., Court, J.A., Bonham, J.R., Rodway, M. and Atack, J.R., Interaction of 9-amino-1,2,3,4-tertahydroamino-acridine (THA) with human cortical nicotinic and muscarinic receptor binding in vitro, Neurosci. Lett., 91 (1988) 211-216.
27. [27] Potter, L.T., Ferrendelli, C.A., Hanchett, H.E., Hollifield, M.A. and Lorenzi, M.V., Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors, Mol. Pharmacol., 35 (1989) 652-660.
28. [28] Potter, P.E., Nitta, S., Chaudhry, J., Lalezari, I., Goldiner, P. and Foldes, F.F., Effects of LF-14, THA and physostigmine in rat hippocampus and cerebral cortex, Neurochem. Int., 14 (1989) 433-438.
29. [29] Richardson, I.W. and Szerb, J.C., The release of labelled acetylcholine and choline from cerebral cortical slices stimulated electrically, Br. J. Pharmacol., 52 (1974) 499-507.
30. [30] Svensson, A.-L., Alafuzoff, I. and Nordberg, A., Characterization of muscarinic receptor subtypes in Alzheimer and control cortices by selective muscarinic antagonists, Brain Res., 596 (1992) 142-148.
31. [31] Vizi E.S., Kobayashi, O., Töröcik, A., Kinjo, M., Nagashima, H., Manabe, N., Goldiner, P.L., Potter, P.E. and Foldes, F.F., Heterogeneity of presynaptic muscarinic receptors involved in modulation of transmitter release, Neuroscience, 31 (1989) 259-267.
32. [32] Wagstaff, A.J. and McTavish, D., Tacrine, A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in Alzheimer's disease, Drug Aging, 4 (1994) 510-540.